Interim report
Page 1
BIOGEN PHARMACHEM INDUSTRIES LIMITED CIN NO: L51100GJ1995PLC026702 (Formerly Known as SUN TECHNO OVERSEAS LIMITED) Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001 E mail biogenpharmachem@gmail.com Date: 07.11.2025 To, Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Ref: Scrip Code: 531752 Scrip ID: BIOGEN Dear Sir / Madam, Sub: Outcome of the Board Meeting of the board held on 7th November 2025. Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 07th November 2025 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2025. The board meeting commented at 03:30 PM and concluded at 04:00 PM Please take the above intimation in your records. Thanking You. FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED Kelash Bunkar Director
Page 2
(Rs. In lacs) (Refer Notes Below) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 INCOME (a) Revenue From Operation - - - - - - (b) Other Income (10.49) 154.28 (65.05) 143.79 (74.15) 83.84 Total Income from Operations (Net) (10.49) 154.28 (65.05) 143.79 (74.15) 83.84 2 EXPENSES - (a) Cost of material consumed - - - - - - (b) Changes in inventories of finished goods, work-in-progress, and stock-in-trade - - - - - - (c) Employee benefit expense 5.13 6.33 1.03 11.46 2.41 16.79 (d) Finance Costs - - - - - - (e) Depreciation and amortization expense - - - - - (f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately) 33.54 13.47 33.65 47.01 39.00 96.32 Total Expenses 38.67 19.80 34.68 58.47 41.41 113.11 3 Profit / (Loss) from operations before exceptional items Tax (1-2) (49.15) 134.48 (99.73) 85.33 (115.56) (29.27) 4 Exceptional Items - - - - - - 5 Profit / (Loss) before Tax (3 ± 4) (49.15) 134.48 (99.73) 85.33 (115.56) (29.27) 6 Tax Expense - - - - - - 7 Net Profit / (Loss) after Tax (5 - 6) (49.15) 134.48 (99.73) 85.33 (115.56) (29.27) 8 Other Comprehensive Income (net of tax ) - - - - - - 9 Total Comprehensive Income for the period (7 ± 8) (49.15) 134.48 (99.73) 85.33 (115.56) (29.27) 10 Paid-up equity share capital (Face Value of Rs.1/- each) 9,026.03 9,026.03 6,526.03 9,026.03 6,526.03 6,526.03 11 Other Equity - - - - - (903.26) 12 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic (0.01) 0.01 (0.02) 0.01 (0.02) (0.00) (b) Diluted (0.01) 0.01 (0.02) 0.01 (0.02) (0.00) Biogen Pharmachem Industries Limited Email:- suntechnooverseas@gmail.com Particulars CIN:- L65910GJ1995PLC026702 30-Sep-25 Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2025 30-Sep-24 Six Months Ended Sl no. Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Quarter Ended 30-Sep-24 30-Sep-25 Year Ended 31 Mar 202530-Jun-25
Page 3
(Rs. in Lakhs) Standalone Statement of Assets and Liabilities As at 30th September, 2025 As at 31st March, 2025 Particulars Un-Audited Audited A ASSETS 1 Non-current assets Property, plant and equipment - - Capital work-in-progress - - Other intangible assets - - Investments in subsidiaries, associates and joint ventures - - Financial assets Investments 2,137.10 2,384.41 Loans 7,549.39 6,551.73 Other financial assets - - Income Tax assets (net) - - Deferred tax assets (net) - - Other non-current assets - - Sub-total - Non-Current Assets 9,686.49 8,936.14 2 Current assets Inventories - - Financial assets Investments - - Trade receivables - - Cash and cash equivalents 5.45 5.48 Bank balances other than Cash and Cash equivalents above 31.05 196.15 Loans, Current 8.51 7.33 Other financial assets - - Other current assets 186.02 56.67 Assets classified as held for sale - - Sub-total - Current Assets 231.04 265.63 TOTAL - ASSETS 9,917.53 9,201.77 B EQUITY AND LIABILITIES 1 Equity Equity Share capital 9,026.03 6,526.03 Other equity 882.07 2,666.74 Sub-total - Shareholders' funds 9,908.10 9,192.77 2 LIABILITIES Non-current liabilities Financial liabilities Borrowings, non-Current - - Provisions - - Income tax liabilities (net) - - Other non-current liabilities - - Sub-total - Non-current liabilities - - 3 Current liabilities Financial liabilities Borrowings, Current - - Trade payables, Current - - Other financial liabilities - - Other current liabilities 9.43 9.00 Provisions - - Current tax liabilities (net) - - Sub-total - Current liabilities 9.43 9.00 TOTAL - EQUITY AND LIABILITIES 9,917.53 9,201.77 Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com
Page 4
1 2 3 4 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Biogen Pharmachem Industries Limited Place : Rajkot Kelash Bunkar Date : 07th November, 2025 Wholetime Director Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com Notes: The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The Statutory Auditors have carried out a limited review of the above financial result. Company has only one segment and hence no separate segment result has been given. The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
Page 5
(Rs. in Lakhs, unless otherwise stated) 30.09.2025 30.09.2024 Rupees Rupees A. CASH FLOW FROM OPERATING ACTIVITIES: Profit before tax 85.33 115.56- Adjustment For : Share of (profit)/loss from investment in partnership firm - - Depreciation/amortization on continuing operation - - Pre-operating Expense - Interest expenses - - Operating profit before working capital changes 85.33 115.56- Movement in Working Capital : Increase/(decrease) in Inventory - - Increase/(decrease) in Trade receivables - - Increase/(decrease) in Short Term Loan & Advances 1.18- - Increase/(decrease) in Current Liabilities 0.43 21.10- Increase/(decrease) in Trade Payable - - Increase/(decrease) in Other Current Assets 129.35- 150.04- Direct taxes paid (net of refunds) - Net Cash Flow from Operating Activities(A) 44.78- 286.70- B. CASH FLOW FROM INVESTING ACTIVITIES Investments in Equity Instruments 247.31 270.90 Purchase / Sale of Fixed Assets - - Increase/(decrease) in Long Term Loan & Advances 997.66- 46.40 Net Cash Flow from Invesing Activities(B) 750.35- 317.30 C. CASH FLOW FROM FINANCING ACTIVITIES Proceed (Repayment) from long term borrowing - - Proceed (Repayment) from short term borrowing - - Proceed from Preferenital Warrants 630.00 - Net Cash Flow from Financing Activities(C) 630.00 - Net increase/(decrease) in cash & cash equivalents(A+B+C) 165.13- 30.60 Cash and Cash equivalents (Opening Balance) 201.63 1.69 Cash and Cash equivalents (Closing Balance) 36.50 32.29 As per our report of even date For, Rishi Sekhri and Associates, For and on Behalf of the Board Chartered Accountants For, Biogen Pharmachem Industries Limited FRN: 128216w SD/- CA Rishi Sekhri Partner Kelash Bunkar M.NO. 126656 Wholetime Director Place: Mumbai Place: Rajkot Date : 07th November, 2025 Date : 07th November, 2025 Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025 Particulars Previous year figure have been regrouped/ reclassified wherever necessary
Page 6
, RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS GROUND FLOOR. BANDRAARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050. Tel.: 9820501848, Email: rishisekhri@gmail.co m Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligat ions and Disclosure Requirements) Regulations, 2015, as amended Review Report To The Board of Directors Biogen Pharmachem Industries limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Biogen Pharmachem Industrie s Limited (the "Company") for the quarter ended September 30, 202S and year to date from April 01, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (lnd AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles genera lly accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independen t Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review of interim financial information consists of making inquiri es, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obta in assurance that we wou ld become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has com~ to our attent ion that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the mann~r in ,which it is to be disclosed, or that it contains any material misstatement. PLACE: Mumbai Date: 07/11/2025 UDIN: 251266S6NTKTCK61S • -